CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-08 | COUGHLIN TIMOTHY Director | Grant or award | +6,500 | 49,000 | ||
| 2024-05-08 | COUGHLIN TIMOTHY Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2024-05-08 | Bruhn Suzanne Louise Director | Grant or award | +6,500 | 22,250 | ||
| 2024-05-08 | Bruhn Suzanne Louise Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2024-05-08 | Baynes Roy D. Director | Grant or award | +6,500 | 31,000 | ||
| 2024-05-08 | Baynes Roy D. Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2024-04-11 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −54 | $6.74 | $364 | 70,849 |
| 2024-02-01 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale | −9,106 | $8.53 | $78K | 360,616 |
| 2024-02-01 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale | −10,016 | $8.86 | $89K | 350,600 |
| 2024-02-01 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale | −2,174 | $8.53 | $19K | 83,310 |
| 2024-02-01 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale | −2,590 | $8.86 | $23K | 80,720 |
| 2024-02-01 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale | −2,174 | $8.53 | $19K | 78,860 |
| 2024-02-01 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale | −2,590 | $8.86 | $23K | 76,270 |
| 2024-02-01 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −4,195 | $8.53 | $36K | 99,503 |
| 2024-02-01 | Inrig Jula CHIEF MEDICAL OFFICER | Sale | −2,174 | $8.53 | $19K | 58,074 |
| 2024-02-01 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −3,818 | $8.53 | $33K | 70,903 |
| 2024-02-01 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale | −2,820 | $8.53 | $24K | 52,017 |
| 2024-01-31 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award | +135,000 | 369,722 | ||
| 2024-01-31 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award · Employee stock option (right to buy) | +360,000 | 360,000 | ||
| 2024-01-31 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Grant or award | +25,000 | 85,484 |
Page 24 of 51 · 1,020 trades